To identify genes controlling volatile anesthetic (VA) action, we have screened through existing Caenorhabditis elegans mutants and found that strains with a reduction in Go signaling are VA resistant. Loss-of-function mutants of the gene goa-l, which codes for the alpha -subunit of Go, have EC(50)s for the VA isoflurane of 1.7- to 2.4-fold that of wild type. Strains overexpressing
egl-10, which codes for an RGS protein negatively regulating goa-l, are also isoflurane resistant. However, sensitivity to halothane, a structurally distinct VA, is differentially affected by Go pathway mutants. The RGS overexpressing strains, a goa-l missense mutant found to carry a novel mutation near the GTP-binding domain, and
eat-16(rf) mutants, which suppress
goa-1(gf) mutations, are all halothane resistant;
gon-1(null) mutants have wild-type sensitivities. Double mutant strains carrying mutations in both goa-l and
unc-64, which codes for a neuronal syntaxin previously found to regulate VA sensitivity, show that the syntaxin mutant phenotypes depend in part on goa-l expression. Pharmacological assays using the cholinesterase inhibitor aldicarb suggest that VAs and GOA-1 similarly downregulate cholinergic neurotransmitter release in C. elegans. Thus, the mechanism of action of VAs in C. elegans is regulated by Goa, and presynaptic Go alpha -effectors are candidate VA molecular targets.